We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Platform Captures Extracellular Vesicles for Early Cancer Detection

By LabMedica International staff writers
Posted on 05 May 2026

Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce and short-lived, limiting the reliability of simple tests. Detecting robust signals that appear before symptoms is a persistent challenge for laboratories.

At the University of Calgary’s Schulich School of Engineering, investigators have developed EXOSense, a platform designed to isolate small extracellular vesicles directly from blood and other bodily fluids. These vesicles are released by cells and can carry disease-related information both internally and on their surface. The effort targets the creation of simple liquid biopsy tests that fit within routine laboratory workflows.


Image: Abstract (Tamrin SH, Sanati Nezhad A, Sen A. ACS Omega. 2025;10(50):61568–61579. doi:10.1021/acsomega.5c07331)
Image: Abstract (Tamrin SH, Sanati Nezhad A, Sen A. ACS Omega. 2025;10(50):61568–61579. doi:10.1021/acsomega.5c07331)

EXOSense leverages the vesicles’ natural electrical properties to capture them without adding external labels such as antibodies, preserving their native state for analysis. The technology gently collects vesicles using electrical force so their information is maintained, addressing a long-standing challenge of isolating extremely small particles that are mixed within complex fluids. By maintaining label-free conditions, the approach is intended to keep biological signals intact and make subsequent analyses more accurate.

Recent work by the team published in ACS Omega indicates that the electrical signals of these particles could provide a fast, label-free route to diagnostic readouts. The platform is patent pending and remains under development, with testing on patient samples still required. Development focuses on microfluidic miniaturization to create user-friendly, cost-effective formats that can broaden access, including in underserved settings. Over time, the group anticipates a test capable of early cancer detection from a small volume of biofluid, with the goal of helping to reduce the overall burden of cancer.

Related Links
University of Calgary Schulich School of Engineering


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Immunofluorescence Analyzer
IFA System
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Latest Technology News

Autonomous Robotic System Receives FDA Authorization for Blood Collection
05 May 2026  |   Technology

Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
05 May 2026  |   Technology

Training Device Improves Accuracy of Pooled Molecular Diagnostics
05 May 2026  |   Technology